¿La espironolactona será la heroína que conquiste el corazón en hemodiálisis?
Descúbrelo en la travesía del ensayo ACHIEVE y únete a la discusión en #NephJC.
In ESRD is spironolactone an overACHIEVEr?
The ACHIEVE visual abstract
Does spironolactone decrease cardiovascular disease and heart failure hospitalizations in patients on dialysis?
Check out this crisp VA by Dr Akshaya Jayachandran.
#NephJC Summer Book Club Everything Is Tuberculosis poetry
#NephJC Summer Bookclub: Everything is Tuberculosis by John Green
The summer book club started in 2015, with one of the best books we have done in book club, Atul Gawande's Being Mortal. I think it should be required reading for all physicians. So now, in 2025, it is the NephJC Summer Book’s tenth anniversary (which represents our eleventh book). The history has been rich:
Ensayo HiLo: el resumen visual
Aunque sabemos que el fósforo elevado se asocia consistentemente con mayor mortalidad y eventos cardiovasculares, aún no existe evidencia definitiva de que bajarlo de forma agresiva cambie el pronóstico.
Revisemos el resumen visual del estudio HiLo, creado Sejal Lakhani que evaluó objetivos altos vs. bajos de fósforo sérico en pacientes en hemodiálisis.
The HiLo Trial - Visual Abstract
Is a lower versus higher phosphate target beneficial to patients undergoing hemodialysis?
Check out this crisp VA by Dr Sejal Lakhani
High or Low Phosphate? Are we Missing the (P)oint?
NephJC Shorts: Should we Screen for Kidney Disease?
eGFR perspectives on the difference between Cystatin C and creatinine
Check out the summary on eGFR diference chat, done by NephJC intern Bogdan Agavriloaei
Las Perspectivas del estudio CRIC: el Resumen Visual
Basado en los datos del estudio CRIC, este análisis profundiza en si esa discordancia (TFGe dif) es solo “ruido”… o una señal clínica que hemos estado ignorando.
Echale un vistazo al resumen visual realizado por el equipo de internos de #NephJC Dr Sai Vani Yellampalli y Akshaya Jayachandran
Insights from the CRIC Study: Visual Abstract
Based on data from the CRIC study, this analysis dives deep into whether this lab mismatch is just noise… or a clinical signal we’ve been missing.
Check out the beautiful visual abstract made by our NephJC interns Sai Vani Yellampalli and Akshaya Jayachandran. Great team work!!!
Mind The Gap: When eGFR Creatinine and Cystatin C Disagree
NephJC Shorts: The end of the Fluid Wars?
NephJC Shorts: zilebesiran silencing hypertension via RNA interference
CONFIDENCE manifests: finerenone & empagliflozin – CKD power couple that’s redefining ‘renal romance’
Check out CONFIDENCE recap
A dose of CONFIDENCE: Building evidence for finerenone-empagliflozin synergy in diabetic kidney disease
CONFIDENCE Visual Abstract
Check out the beautiful visual abstract made by NephJC intern Michelle Fravel.
Resumen Visual Ensayo CONFIDENCE
El ensayo CONFIDENCE evaluó la combinación de finerenona + empagliflozina en ERC + DM2: mayor reducción de CACu a 180 días. ¿Estamos listos para iniciar la terapia combinada desde el principio?
Revisa el resumen visual por Michelle Fravel
